Zoetis Inc. (NYSE:ZTS) Given Consensus Rating of “Buy” by Brokerages

Shares of Zoetis Inc. (NYSE:ZTS) have been given an average rating of “Buy” by the nine analysts that are covering the company, Marketbeat reports. Eight research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average 1 year price target among brokerages that have updated their coverage on the stock in the last year is $217.11.

Several equities research analysts have recently weighed in on the company. The Goldman Sachs Group reduced their price target on Zoetis from $223.00 to $196.00 and set a “buy” rating on the stock in a report on Monday, May 6th. BTIG Research lifted their target price on Zoetis from $220.00 to $225.00 and gave the stock a “buy” rating in a research report on Monday, August 12th. Piper Sandler upped their price target on shares of Zoetis from $195.00 to $210.00 and gave the stock an “overweight” rating in a report on Wednesday, August 14th. Stifel Nicolaus raised their price target on shares of Zoetis from $180.00 to $200.00 and gave the stock a “buy” rating in a research note on Monday, August 5th. Finally, Argus raised shares of Zoetis to a “strong-buy” rating in a research report on Friday, August 9th.

Institutional Investors Weigh In On Zoetis

Large investors have recently modified their holdings of the business. Focus Financial Network Inc. ADV bought a new position in Zoetis in the fourth quarter worth approximately $2,159,000. Price T Rowe Associates Inc. MD boosted its position in Zoetis by 31.0% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 13,716,681 shares of the company’s stock valued at $2,707,262,000 after purchasing an additional 3,244,074 shares in the last quarter. Ninety One UK Ltd raised its holdings in Zoetis by 13.1% in the fourth quarter. Ninety One UK Ltd now owns 108,293 shares of the company’s stock worth $21,374,000 after purchasing an additional 12,537 shares in the last quarter. Axiom Investors LLC DE lifted its position in shares of Zoetis by 36.3% during the fourth quarter. Axiom Investors LLC DE now owns 594,474 shares of the company’s stock valued at $117,331,000 after buying an additional 158,459 shares during the last quarter. Finally, Global Assets Advisory LLC bought a new stake in shares of Zoetis in the 1st quarter valued at about $8,831,000. Institutional investors own 92.80% of the company’s stock.

Zoetis Stock Down 0.7 %

NYSE ZTS opened at $180.96 on Friday. Zoetis has a 52 week low of $144.80 and a 52 week high of $201.92. The firm has a market capitalization of $82.57 billion, a price-to-earnings ratio of 34.87, a PEG ratio of 2.81 and a beta of 0.86. The company has a quick ratio of 2.09, a current ratio of 3.45 and a debt-to-equity ratio of 1.32. The company has a fifty day moving average of $178.56 and a two-hundred day moving average of $175.08.

Zoetis (NYSE:ZTS) last issued its quarterly earnings results on Tuesday, August 6th. The company reported $1.56 EPS for the quarter, beating the consensus estimate of $1.49 by $0.07. Zoetis had a net margin of 26.29% and a return on equity of 50.67%. The company had revenue of $2.36 billion for the quarter, compared to the consensus estimate of $2.31 billion. During the same period in the prior year, the firm posted $1.41 EPS. The firm’s revenue was up 8.3% compared to the same quarter last year. On average, analysts predict that Zoetis will post 5.84 earnings per share for the current year.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.